Abstract
Vaccines have formed a rare bright spot in the ongoing COVID-19 pandemic. The rapid and successful deployment of several new vaccines offers a way out of this crisis, now threatened more by vaccine hesitancy than anything else. Unfortunately, recent reports of thromboembolic (TE) events with both adenoviral vector vaccines, cerebral venous sinus thrombus (CVST) with Johnson and Johnson/Janssen (JJ) vaccine, and other clotting concerns with the Oxford AstraZeneca (AZ) may amplify vaccine hesitancy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
